| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC1A6 |
| Uniprot No | P48664 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 149-271aa |
| 氨基酸序列 | MVTIIHPGKGSKEGLHREGRIETIPTADAFMDLIRNMFPPNLVEACFKQFKTQYSTRVVTRTMVRTENGSEPGASMPPPFSVENGTSFLENVTRALGTLQEMLSFEETVPVPGSANGINALGL |
| 预测分子量 | 40.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC1A6(EAAT4)重组蛋白的3篇假设参考文献，基于典型研究方向的概括：
---
1. **文献名称**：*Functional Characterization of Recombinant Human SLC1A6 (EAAT4) Expressed in Mammalian Cells*
**作者**：Kavanaugh, M.P., et al.
**摘要**：本研究报道了人源SLC1A6基因在HEK293细胞中的重组表达与功能分析。通过放射性标记谷氨酸摄取实验，证实重组SLC1A6具有高亲和力谷氨酸转运活性，且依赖钠/钾离子梯度。研究还发现，该蛋白对特定抑制剂(如TBOA)敏感，提示其潜在药理学调控机制。
2. **文献名称**：*Structural Insights into EAAT4 through Cryo-EM Analysis of Recombinant Protein*
**作者**：Grewer, C., et al.
**摘要**：利用昆虫细胞系统表达并纯化SLC1A6重组蛋白，结合冷冻电镜技术解析其三维结构。结果表明，SLC1A6形成三聚体结构，跨膜域中存在独特的构象变化，为理解谷氨酸转运及疾病相关突变机制提供结构基础。
3. **文献名称**：*Role of SLC1A6 Mutants in Cerebellar Ataxia: Recombinant Protein-Based Functional Assays*
**作者**：Lin, C.L.G., et al.
**摘要**：通过构建SLC1A6致病突变体的重组蛋白，在细胞模型中评估其转运功能。实验发现部分突变导致谷氨酸摄取效率显著下降，且细胞膜定位异常，提示SLC1A6功能缺陷与小脑共济失调的病理关联。
---
注：上述文献为示例性质，实际引用时需以真实发表论文为准。建议通过PubMed或Web of Science以“SLC1A6 recombinant”“EAAT4 expression”等关键词检索最新文献。
**Background of SLC1A6 Recombinant Protein**
SLC1A6. also known as excitatory amino acid transporter 4 (EAAT4), is a member of the solute carrier 1 (SLC1A) family, which comprises high-affinity glutamate transporters. These transporters play critical roles in maintaining extracellular glutamate homeostasis within the central nervous system (CNS) by rapidly clearing synaptic glutamate, thereby preventing excitotoxicity and ensuring proper neurotransmission. SLC1A6 is predominantly expressed in cerebellar Purkinje cells and astrocytes, where it contributes to glutamate uptake and recycling.
The recombinant SLC1A6 protein is engineered through molecular cloning techniques, typically expressed in heterologous systems like mammalian (e.g., HEK293) or insect cells to ensure proper post-translational modifications and functional folding. This recombinant form allows researchers to study the protein’s structure, kinetics, and regulatory mechanisms in vitro. Key research areas include elucidating its substrate specificity, ion coupling (Na⁺/K⁺-dependent transport), and interaction with regulatory proteins or pharmacological agents.
Dysregulation of SLC1A6 has been implicated in neurological disorders such as epilepsy, neurodegenerative diseases, and cerebellar ataxia, highlighting its therapeutic potential. Recombinant SLC1A6 serves as a vital tool for drug screening, mechanistic studies of glutamate transport pathologies, and developing targeted therapies. Additionally, structural analyses using recombinant protein help map binding sites and design modulators to enhance transporter activity or mitigate dysfunction. Its study also advances understanding of broader SLC1A family functions in CNS health and disease.
In summary, SLC1A6 recombinant protein bridges molecular neuroscience and translational research, offering insights into glutamate dynamics and pathways for treating glutamate-related disorders.
×
